Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer

Inclusion Criteria: * 1\) Histological confirmed prostatic carcinoma patient * 2\) Hormone non-respondence ex1) Although treatment PSA ≥ 5ng/ml ex2) PSA level were measured two times ex3) Prior one year radiology were processed * 3\) Just 18 years over * 4\) Has a score ≤1 on the ECOG Performance Scale * 5\) Expected survival life time ≥ 6month * 6\) Adequate bone marrow function hemoglobin ≥ 10.0g/dL , leukocyte count ≥ 4,000/mm3 thrombocyte ≥ 100,000/mm3 * 7\) Adequate blood coagulation function PT(INR) \< 1.5, aPTT\< 1.5 x control * 8\) Adequate kidney function Normal blood upper level Creatinine ≤ 1.5 times * 9\) Adequate liver function Normal blood upper level AST/ALT ≤ 1.5 times * 10\) Autoimmune antibody system don't have disorder ex) anti-nuclear antibody, anti-thyroglobulin antibody negativity * 11\) Person who didn't treat prior 6 weeks operation, radiotherapy treatment,immunotherapy or chemotherapy * 12\) Patient who voluntarily participated clinical trial and confirmed a written consent Exclusion Criteria: * 1\) Having other malignancy or previous history of malignancy * 2\) Brain metastases patient * 3\) Having autoimmune disease or its history * 4\) Pyrexia, rigor, leukocytosis infectious disease * 5\) HBsAg, anti-HCV, HIV positive patient * 6\) Myocardial infarction, cardiac insufficiency, other severe heart disease and non-controlled hypertension * 7\) Severe and active medical disease * 8\) Mental history disease or epilepsy * 9\) Patients participated other clinical trial within 4 weeks * 10\) Patients impossible to participate this trial by investigator's decision * 11\) Patients who received immunosuppressant such as steroid, cyclosporin A, azathioprine within 6 weeks